Skip to main content

Table 2 Univariate and multivariate analyses for PFS

From: Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts

Variable (comparator)

Progression free survival

Univariate analysis

Multivariate analysis

HR (95% CI)

p-value

HR (95% CI)

p-value

BMI (< 25 vs ≥ 25)

1.71 (1.09–2.67)

0.0182

1.73 (1.09–2.74)

0.0184

Primary tumor (NSCLC)

 Melanoma

0.53 (0.29–0.99)

0.0463

0.48 (0.26–0.91)

0.0236

 Kidney

0.75 (0.39–1.43)

0.3880

0.59 (0.31–1.48)

0.1223

 Others

0.77 (0.27–2.13)

0.6191

0.80 (0.28–2.23)

0.6715

Sex (Male vs Female)

1.23 (0.76–1.99)

0.3881

1.15 (0.71–1.87)

0.5734

Age (Elderly vs Non-elderly)

1.04 (0.66–1.61)

0.8570

–

–

Treatment line (Non-first vs First)

1.72 (0.96–3.06)

0.0639

–

–

Burden of disease (> 2 vs ≤ 2 sites)

1.20 (0.75–1.92)

0.4295

–

–

ECOG PS (≥ 2 vs 0–1)

2.29 (1.86–4.70)

< 0.0001

2.94 (1.84–4.69)

< 0.0001